ARS Pharmaceuticals, Inc. 8-K

What Happened

• On May 15, 2026, ARS Pharmaceuticals, Inc. (SPRY) announced its financial results for the quarter and year ended March 31, 2026 via a press release (filed as Exhibit 99.1 to the Form 8-K).
• The company also updated its corporate/investor presentation (filed as Exhibit 99.2) and made the revised presentation available on its website. The Form 8-K was signed by Richard Lowenthal, President and CEO.

Key Details

• Date of disclosure: May 15, 2026.
• Period covered: quarter and fiscal year ended March 31, 2026.
• Exhibits filed: Exhibit 99.1 (Press Release dated May 15, 2026) and Exhibit 99.2 (Company Presentation dated May 15, 2026).
• Form 8-K items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

Why It Matters

• The filing signals the company has released its latest quarterly and full-year financial results and updated investor materials—both are primary sources for revenue, earnings, cash position, and management commentary.
• Retail investors should review the press release and updated presentation on ARS’s website (or in the 8-K exhibits) to see the actual financial figures, guidance (if any), and management discussion before making investment decisions.